Lacosamide G.L. Pharma Gmbh (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This stabilizes the inactive state of the channels, decreasing repetitive neuronal firing and lowering overall neuronal excitability, which helps prevent seizure propagation.

The specific dose of Lacosamide is determined by the prescribing clinician based on the individual’s medical condition, age, renal function and response to therapy. The prescriber will start with a recommended initial dose and may adjust it as needed.

Safety data for Lacosamide in pregnancy and lactation are limited. It is classified as having an unknown pregnancy category, so it should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lacosamide G.L. Pharma Gmbh. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with traditional sodium‑channel blockers such as carbamazepine, Lacosamide selectively enhances slow inactivation rather than fast inactivation, which may result in a different side‑effect profile and lower risk of certain cardiac effects. Its unique mechanism can be advantageous for patients who have not responded adequately to other agents.

Lacosamide oral tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Lacosamide is administered orally as a tablet. The tablet should be swallowed whole with water and taken with or without food, as directed by the prescribing healthcare professional.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, and the emergence of suicidal thoughts or behaviors. Patients should be monitored for any signs of these conditions and seek immediate medical attention if they occur.

Lacosamide is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is also advised for individuals with significant cardiac conduction disorders, severe renal impairment, or those taking other medications that markedly affect cardiac rhythm.